Abstract
Immunotherapy is treatment that uses a person's own immune system to fight cancer. Pembrolizumab is a humanized IgG4 monoclonal antibody that targets the PD-1 receptor (Programmed cell death protein 1 receptor).
Pembrolizumab demonstrated efficacy as first-line therapy for metastatic NSCLC. In the Czech Republic, pembrolizumab monotherapy has reimbursement as the first-line treatment of metastatic NSCLC in adults whose tumours express PD-L1 >= 50 %, with no EGFR or ALK positive tumour mutations in case of nonsquamous NSCLC.
This year, there is new pembrolizumab reimbursement in combination with chemotherapy, as the first-line treatment of metastatic NSCLC in adults whose tumours express PD-L1 1-49 %, with no EGFR or ALK positive tumour mutations in case of nonsquamous NSCLC. We report the case of a 69-year-old male patient who presented with metastatic NSCLC.
The patient received pembrolizumab monotherapy and there is complete response to pembrolizumab. The patient developed immune-mediated colitis successfully treated with mesalazine.